share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

诺瓦瓦克斯医药 | 4：持股变动声明-高管 Dubovsky Filip
美股sec公告 ·  06/20 17:12
Moomoo AI 已提取核心信息
On June 17, 2024, Novavax's President of R&D, Filip Dubovsky, completed a series of transactions involving the company's common stock. Dubovsky executed the sale of 13,904 shares at prices ranging from $14.46 to $14.54 per share, resulting in a total market value of $201,164.16. Prior to the sales, Dubovsky acquired the same number of shares through the exercise of derivative securities at prices between $6.09 and $6.97. Following these transactions, Dubovsky's direct holdings in Novavax common stock amounted to 66,613 shares.
On June 17, 2024, Novavax's President of R&D, Filip Dubovsky, completed a series of transactions involving the company's common stock. Dubovsky executed the sale of 13,904 shares at prices ranging from $14.46 to $14.54 per share, resulting in a total market value of $201,164.16. Prior to the sales, Dubovsky acquired the same number of shares through the exercise of derivative securities at prices between $6.09 and $6.97. Following these transactions, Dubovsky's direct holdings in Novavax common stock amounted to 66,613 shares.
2024年6月17日，诺瓦瓦克斯医药的研发总裁Filip Dubovsky完成了一系列涉及该公司普通股的交易。Dubovsky以每股14.46美元至14.54美元的价格出售了13,904股，总市值为201,164.16美元。在进行销售之前，Dubovsky以6.09美元至6.97美元的价格通过衍生证券行权获取了相同数量的股份。在这些交易后，Dubovsky在诺瓦瓦克斯医药的普通股中的直接持股总数为66,613股。
2024年6月17日，诺瓦瓦克斯医药的研发总裁Filip Dubovsky完成了一系列涉及该公司普通股的交易。Dubovsky以每股14.46美元至14.54美元的价格出售了13,904股，总市值为201,164.16美元。在进行销售之前，Dubovsky以6.09美元至6.97美元的价格通过衍生证券行权获取了相同数量的股份。在这些交易后，Dubovsky在诺瓦瓦克斯医药的普通股中的直接持股总数为66,613股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息